Friday, January 30, 2026

North Korea Tells Japan: ‘You Can’t Rewrite WWII History’

North Korea emphasizes moral responsibility for historical accountability with Japan, urging self-reliance and modernization in various sectors.

Marine Commander Challenges Presidential Decree: A Battle for Justice in Military Court

Former Marine Corps Investigative Division Commander Colonel...

Nvidia and Foxconn Are Building a Massive AI Supercomputer in Taiwan

Nvidia partners with Foxconn to build an AI supercomputer in Taiwan, enhancing local AI infrastructure and innovation.

Tag: trial

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

Amid Rising Drug Resistance, Korea Begins DOMINO Trial to Reassess First-Line Treatment for Pediatric Mycoplasma

The DOMINO trial will assess treatments for pediatric Mycoplasma pneumonia, addressing rising macrolide resistance in Korea.

Unlocking Convenience: Rolvedon’s Same-Day Chemotherapy Solution for Neutropenia Revealed

Hanmi Pharmaceutical's Rolvedon shows potential for same-day chemotherapy administration, improving patient convenience and market competitiveness.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

SK Biofarm, FDA Approved Radioactive Method: Will it be a Revolutionary Cancer Cure with SLK 33501?

SK Biopharmaceuticals gains FDA approval for Phase 1 trials of radiopharmaceuticals SKL35501 and SKL35502, advancing cancer treatment.

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.